Objectives

After participating in this educational activity, attendees should be able to:

1. Outline the current approach in the clinic to identifying patients with severe uncontrolled asthma and how to phenotype these patients using current biomarkers

2. Understand the mechanism that underlie airway inflammation in asthma and the mechanisms of action of the emerging biologic drugs and bronchial thermoplasty, and how to select patients for each of these therapies

3. Develop therapies currently in the pipeline for development and how affect the current landscape for treatment

Faculty 

Geoffrey Chupp, MD

Professor of Medicine, Yale School of Medicine

Director, Yale Center for Asthma and Airway Disease

Faculty Disclosure
None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.                               

Dr. Chupp has the following disclosures:

Consultant: GSK, Genentech, Sanofi-Genzyme, Astra Zeneca, Boehringer Ingelheim

Speaker’s Bureau: GSK, Genentech, Sanofi-Genzyme, Astra Zeneca, Boehringer Ingelheim